Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to provide continued protection against severe illness and death...
Gespeichert in:
| Veröffentlicht in: | MMWR. Morbidity and mortality weekly report 2023-10, Vol.72 (42), p.1140-1146 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1146 |
|---|---|
| container_issue | 42 |
| container_start_page | 1140 |
| container_title | MMWR. Morbidity and mortality weekly report |
| container_volume | 72 |
| creator | Regan, Joanna J Moulia, Danielle L Link-Gelles, Ruth Godfrey, Monica Mak, Josephine Najdowski, Morgan Rosenblum, Hannah G Shah, Melisa M Twentyman, Evelyn Meyer, Sarah Peacock, Georgina Thornburg, Natalie Havers, Fiona P Saydah, Sharon Brooks, Oliver Talbot, H. Keipp Lee, Grace M Bell, Beth P Mahon, Barbara E Daley, Matthew F Fleming-Dutra, Katherine E Wallace, Megan |
| description | COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to provide continued protection against severe illness and death from COVID-19. Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines protect against are no longer circulating widely. On September 11, 2023, the Food and Drug Administration (FDA) approved the updated (2023-2024 Formula) COVID-19 mRNA vaccines by Moderna and Pfizer-BioNTech for persons aged ≥12 years and authorized these vaccines for persons aged 6 months-11 years under Emergency Use Authorization (EUA). On October 3, 2023, FDA authorized the updated COVID-19 vaccine by Novavax for use in persons aged ≥12 years under EUA. The updated COVID-19 vaccines include a monovalent XBB.1.5 component, which is meant to broaden vaccine-induced immunity and provide protection against currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19-associated illness and death. On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. These recommendations will be reviewed as new evidence becomes available or new vaccines are approved and might be updated. |
| doi_str_mv | 10.15585/mmwr.mm7242e1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10602621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A770389856</galeid><sourcerecordid>A770389856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c461t-8d9f91d066b89e7e2a8e3d5a186b9bab5ec81034b915d5023e7228160ce30f693</originalsourceid><addsrcrecordid>eNptksFuEzEQhlcIREPgytkCCXFgg70be71cUBQoRCpqRUnFzfJ6ZxOjtR3s3aJy6pUzvALvwPPkSfCmBVEU-zCS55t_fnkmSR4SPCGUcvrcmC9-YkyRTTMgt5IRoVOackY-3k5GmEzLNCMlPUjuhfAJDyfHd5ODvOCU5YyNkl_LAMg1aLmpZQc1mh-fLV6lpERnUiltIaAMZ_n28nsMU3TovOlbiRrn0Qn44GxAs1Us2377ydA7Z7t1eIHeg3LGgI2KeiCifLcGNKvPdXD-As1jVncdxMYWLYzprf66Q9GJl6rTKnbdXv5AS6sHS6dddBaeoVPYdGAq8DtL95M7jWwDPLiO42R5-PrD_G16dPxmMZ8dpWrKSJfyumxKUmPGKl5CAZnkkNdUEs6qspIVBcUJzqdVSWhNoy4UWcYJwwpy3LAyHycvr3Q3fWWgVmA7L1ux8dpIfyGc1OJmxuq1WLlzQTDDGctIVHh0reDd5x5CJzxsnO-CyHhRFrQsGI7Q0_8go4OCtpUWXD-gHJM4Ps4j-vgKXckWhLaNi33VgItZUeCcl8Nwx0m6h1qBhWjSWWh0fL7BT_bw8dZgtNpb8OSfgjXINg7ftf1u5nuVlXcheGj-fh7BYrfEYlhi8WeJ89_p8OSQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2879759760</pqid></control><display><type>article</type><title>Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Regan, Joanna J ; Moulia, Danielle L ; Link-Gelles, Ruth ; Godfrey, Monica ; Mak, Josephine ; Najdowski, Morgan ; Rosenblum, Hannah G ; Shah, Melisa M ; Twentyman, Evelyn ; Meyer, Sarah ; Peacock, Georgina ; Thornburg, Natalie ; Havers, Fiona P ; Saydah, Sharon ; Brooks, Oliver ; Talbot, H. Keipp ; Lee, Grace M ; Bell, Beth P ; Mahon, Barbara E ; Daley, Matthew F ; Fleming-Dutra, Katherine E ; Wallace, Megan</creator><creatorcontrib>Regan, Joanna J ; Moulia, Danielle L ; Link-Gelles, Ruth ; Godfrey, Monica ; Mak, Josephine ; Najdowski, Morgan ; Rosenblum, Hannah G ; Shah, Melisa M ; Twentyman, Evelyn ; Meyer, Sarah ; Peacock, Georgina ; Thornburg, Natalie ; Havers, Fiona P ; Saydah, Sharon ; Brooks, Oliver ; Talbot, H. Keipp ; Lee, Grace M ; Bell, Beth P ; Mahon, Barbara E ; Daley, Matthew F ; Fleming-Dutra, Katherine E ; Wallace, Megan</creatorcontrib><description>COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to provide continued protection against severe illness and death from COVID-19. Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines protect against are no longer circulating widely. On September 11, 2023, the Food and Drug Administration (FDA) approved the updated (2023-2024 Formula) COVID-19 mRNA vaccines by Moderna and Pfizer-BioNTech for persons aged ≥12 years and authorized these vaccines for persons aged 6 months-11 years under Emergency Use Authorization (EUA). On October 3, 2023, FDA authorized the updated COVID-19 vaccine by Novavax for use in persons aged ≥12 years under EUA. The updated COVID-19 vaccines include a monovalent XBB.1.5 component, which is meant to broaden vaccine-induced immunity and provide protection against currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19-associated illness and death. On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. These recommendations will be reviewed as new evidence becomes available or new vaccines are approved and might be updated.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>DOI: 10.15585/mmwr.mm7242e1</identifier><identifier>PMID: 37856366</identifier><language>eng</language><publisher>Atlanta: U.S. Government Printing Office</publisher><subject>Adults ; Age groups ; Clinical trials ; COVID-19 ; COVID-19 vaccines ; Drug approval ; Drug dosages ; FDA approval ; Full Report ; Health surveillance ; Hospitalization ; Illnesses ; Immunization ; Minority & ethnic groups ; mRNA ; mRNA vaccines ; Myocarditis ; Pharmaceutical industry ; Public health ; RNA ; Severe acute respiratory syndrome coronavirus 2 ; Systematic review ; Teenagers ; Vaccination ; Vaccines</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2023-10, Vol.72 (42), p.1140-1146</ispartof><rights>COPYRIGHT 2023 U.S. Government Printing Office</rights><rights>Published 2023. This article is a U.S. Government work and is in the public domain in the USA.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c461t-8d9f91d066b89e7e2a8e3d5a186b9bab5ec81034b915d5023e7228160ce30f693</citedby><cites>FETCH-LOGICAL-c461t-8d9f91d066b89e7e2a8e3d5a186b9bab5ec81034b915d5023e7228160ce30f693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602621/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602621/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Regan, Joanna J</creatorcontrib><creatorcontrib>Moulia, Danielle L</creatorcontrib><creatorcontrib>Link-Gelles, Ruth</creatorcontrib><creatorcontrib>Godfrey, Monica</creatorcontrib><creatorcontrib>Mak, Josephine</creatorcontrib><creatorcontrib>Najdowski, Morgan</creatorcontrib><creatorcontrib>Rosenblum, Hannah G</creatorcontrib><creatorcontrib>Shah, Melisa M</creatorcontrib><creatorcontrib>Twentyman, Evelyn</creatorcontrib><creatorcontrib>Meyer, Sarah</creatorcontrib><creatorcontrib>Peacock, Georgina</creatorcontrib><creatorcontrib>Thornburg, Natalie</creatorcontrib><creatorcontrib>Havers, Fiona P</creatorcontrib><creatorcontrib>Saydah, Sharon</creatorcontrib><creatorcontrib>Brooks, Oliver</creatorcontrib><creatorcontrib>Talbot, H. Keipp</creatorcontrib><creatorcontrib>Lee, Grace M</creatorcontrib><creatorcontrib>Bell, Beth P</creatorcontrib><creatorcontrib>Mahon, Barbara E</creatorcontrib><creatorcontrib>Daley, Matthew F</creatorcontrib><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Wallace, Megan</creatorcontrib><title>Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023</title><title>MMWR. Morbidity and mortality weekly report</title><description>COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to provide continued protection against severe illness and death from COVID-19. Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines protect against are no longer circulating widely. On September 11, 2023, the Food and Drug Administration (FDA) approved the updated (2023-2024 Formula) COVID-19 mRNA vaccines by Moderna and Pfizer-BioNTech for persons aged ≥12 years and authorized these vaccines for persons aged 6 months-11 years under Emergency Use Authorization (EUA). On October 3, 2023, FDA authorized the updated COVID-19 vaccine by Novavax for use in persons aged ≥12 years under EUA. The updated COVID-19 vaccines include a monovalent XBB.1.5 component, which is meant to broaden vaccine-induced immunity and provide protection against currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19-associated illness and death. On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. These recommendations will be reviewed as new evidence becomes available or new vaccines are approved and might be updated.</description><subject>Adults</subject><subject>Age groups</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Drug approval</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Full Report</subject><subject>Health surveillance</subject><subject>Hospitalization</subject><subject>Illnesses</subject><subject>Immunization</subject><subject>Minority & ethnic groups</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Myocarditis</subject><subject>Pharmaceutical industry</subject><subject>Public health</subject><subject>RNA</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Systematic review</subject><subject>Teenagers</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptksFuEzEQhlcIREPgytkCCXFgg70be71cUBQoRCpqRUnFzfJ6ZxOjtR3s3aJy6pUzvALvwPPkSfCmBVEU-zCS55t_fnkmSR4SPCGUcvrcmC9-YkyRTTMgt5IRoVOackY-3k5GmEzLNCMlPUjuhfAJDyfHd5ODvOCU5YyNkl_LAMg1aLmpZQc1mh-fLV6lpERnUiltIaAMZ_n28nsMU3TovOlbiRrn0Qn44GxAs1Us2377ydA7Z7t1eIHeg3LGgI2KeiCifLcGNKvPdXD-As1jVncdxMYWLYzprf66Q9GJl6rTKnbdXv5AS6sHS6dddBaeoVPYdGAq8DtL95M7jWwDPLiO42R5-PrD_G16dPxmMZ8dpWrKSJfyumxKUmPGKl5CAZnkkNdUEs6qspIVBcUJzqdVSWhNoy4UWcYJwwpy3LAyHycvr3Q3fWWgVmA7L1ux8dpIfyGc1OJmxuq1WLlzQTDDGctIVHh0reDd5x5CJzxsnO-CyHhRFrQsGI7Q0_8go4OCtpUWXD-gHJM4Ps4j-vgKXckWhLaNi33VgItZUeCcl8Nwx0m6h1qBhWjSWWh0fL7BT_bw8dZgtNpb8OSfgjXINg7ftf1u5nuVlXcheGj-fh7BYrfEYlhi8WeJ89_p8OSQ</recordid><startdate>20231020</startdate><enddate>20231020</enddate><creator>Regan, Joanna J</creator><creator>Moulia, Danielle L</creator><creator>Link-Gelles, Ruth</creator><creator>Godfrey, Monica</creator><creator>Mak, Josephine</creator><creator>Najdowski, Morgan</creator><creator>Rosenblum, Hannah G</creator><creator>Shah, Melisa M</creator><creator>Twentyman, Evelyn</creator><creator>Meyer, Sarah</creator><creator>Peacock, Georgina</creator><creator>Thornburg, Natalie</creator><creator>Havers, Fiona P</creator><creator>Saydah, Sharon</creator><creator>Brooks, Oliver</creator><creator>Talbot, H. Keipp</creator><creator>Lee, Grace M</creator><creator>Bell, Beth P</creator><creator>Mahon, Barbara E</creator><creator>Daley, Matthew F</creator><creator>Fleming-Dutra, Katherine E</creator><creator>Wallace, Megan</creator><general>U.S. Government Printing Office</general><general>U.S. Center for Disease Control</general><general>Centers for Disease Control and Prevention</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88F</scope><scope>88J</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M1Q</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>5PM</scope></search><sort><creationdate>20231020</creationdate><title>Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023</title><author>Regan, Joanna J ; Moulia, Danielle L ; Link-Gelles, Ruth ; Godfrey, Monica ; Mak, Josephine ; Najdowski, Morgan ; Rosenblum, Hannah G ; Shah, Melisa M ; Twentyman, Evelyn ; Meyer, Sarah ; Peacock, Georgina ; Thornburg, Natalie ; Havers, Fiona P ; Saydah, Sharon ; Brooks, Oliver ; Talbot, H. Keipp ; Lee, Grace M ; Bell, Beth P ; Mahon, Barbara E ; Daley, Matthew F ; Fleming-Dutra, Katherine E ; Wallace, Megan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c461t-8d9f91d066b89e7e2a8e3d5a186b9bab5ec81034b915d5023e7228160ce30f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adults</topic><topic>Age groups</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Drug approval</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Full Report</topic><topic>Health surveillance</topic><topic>Hospitalization</topic><topic>Illnesses</topic><topic>Immunization</topic><topic>Minority & ethnic groups</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Myocarditis</topic><topic>Pharmaceutical industry</topic><topic>Public health</topic><topic>RNA</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Systematic review</topic><topic>Teenagers</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Regan, Joanna J</creatorcontrib><creatorcontrib>Moulia, Danielle L</creatorcontrib><creatorcontrib>Link-Gelles, Ruth</creatorcontrib><creatorcontrib>Godfrey, Monica</creatorcontrib><creatorcontrib>Mak, Josephine</creatorcontrib><creatorcontrib>Najdowski, Morgan</creatorcontrib><creatorcontrib>Rosenblum, Hannah G</creatorcontrib><creatorcontrib>Shah, Melisa M</creatorcontrib><creatorcontrib>Twentyman, Evelyn</creatorcontrib><creatorcontrib>Meyer, Sarah</creatorcontrib><creatorcontrib>Peacock, Georgina</creatorcontrib><creatorcontrib>Thornburg, Natalie</creatorcontrib><creatorcontrib>Havers, Fiona P</creatorcontrib><creatorcontrib>Saydah, Sharon</creatorcontrib><creatorcontrib>Brooks, Oliver</creatorcontrib><creatorcontrib>Talbot, H. Keipp</creatorcontrib><creatorcontrib>Lee, Grace M</creatorcontrib><creatorcontrib>Bell, Beth P</creatorcontrib><creatorcontrib>Mahon, Barbara E</creatorcontrib><creatorcontrib>Daley, Matthew F</creatorcontrib><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Wallace, Megan</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Military Database</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Regan, Joanna J</au><au>Moulia, Danielle L</au><au>Link-Gelles, Ruth</au><au>Godfrey, Monica</au><au>Mak, Josephine</au><au>Najdowski, Morgan</au><au>Rosenblum, Hannah G</au><au>Shah, Melisa M</au><au>Twentyman, Evelyn</au><au>Meyer, Sarah</au><au>Peacock, Georgina</au><au>Thornburg, Natalie</au><au>Havers, Fiona P</au><au>Saydah, Sharon</au><au>Brooks, Oliver</au><au>Talbot, H. Keipp</au><au>Lee, Grace M</au><au>Bell, Beth P</au><au>Mahon, Barbara E</au><au>Daley, Matthew F</au><au>Fleming-Dutra, Katherine E</au><au>Wallace, Megan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><date>2023-10-20</date><risdate>2023</risdate><volume>72</volume><issue>42</issue><spage>1140</spage><epage>1146</epage><pages>1140-1146</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to provide continued protection against severe illness and death from COVID-19. Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines protect against are no longer circulating widely. On September 11, 2023, the Food and Drug Administration (FDA) approved the updated (2023-2024 Formula) COVID-19 mRNA vaccines by Moderna and Pfizer-BioNTech for persons aged ≥12 years and authorized these vaccines for persons aged 6 months-11 years under Emergency Use Authorization (EUA). On October 3, 2023, FDA authorized the updated COVID-19 vaccine by Novavax for use in persons aged ≥12 years under EUA. The updated COVID-19 vaccines include a monovalent XBB.1.5 component, which is meant to broaden vaccine-induced immunity and provide protection against currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19-associated illness and death. On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. These recommendations will be reviewed as new evidence becomes available or new vaccines are approved and might be updated.</abstract><cop>Atlanta</cop><pub>U.S. Government Printing Office</pub><pmid>37856366</pmid><doi>10.15585/mmwr.mm7242e1</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2195 |
| ispartof | MMWR. Morbidity and mortality weekly report, 2023-10, Vol.72 (42), p.1140-1146 |
| issn | 0149-2195 1545-861X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10602621 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Adults Age groups Clinical trials COVID-19 COVID-19 vaccines Drug approval Drug dosages FDA approval Full Report Health surveillance Hospitalization Illnesses Immunization Minority & ethnic groups mRNA mRNA vaccines Myocarditis Pharmaceutical industry Public health RNA Severe acute respiratory syndrome coronavirus 2 Systematic review Teenagers Vaccination Vaccines |
| title | Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A45%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Updated%20COVID-19%20Vaccines%202023%E2%80%932024%20Formula%20for%20Persons%20Aged%20%E2%89%A56%20Months:%20Recommendations%20of%20the%20Advisory%20Committee%20on%20Immunization%20Practices%20%E2%80%94%20United%20States,%20September%202023&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Regan,%20Joanna%20J&rft.date=2023-10-20&rft.volume=72&rft.issue=42&rft.spage=1140&rft.epage=1146&rft.pages=1140-1146&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/10.15585/mmwr.mm7242e1&rft_dat=%3Cgale_pubme%3EA770389856%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2879759760&rft_id=info:pmid/37856366&rft_galeid=A770389856&rfr_iscdi=true |